Zacks Reiterates Neutral Rating for Eli Lilly and

Home › Zacks Reiterates Neutral Rating for Eli Lilly and

's stock had its "neutral" rating reissued by Zacks in a research report issued on Tuesday. They currently have a $69.00 target price on the stock.

05.10	Eastern North Pacific Tropical Weather Outlook
05.10	Atlantic Tropical Weather Outlook
04.10	Should you tip even if the service wasn't worth it?
04.10	Hurricane Kirk Graphics
04.10	Hurricane Kirk Forecast Discussion Number 22
04.10	Tropical Storm Leslie Forecast Discussion Number 10
04.10	Hurricane Kirk Wind Speed Probabilities Number 22
04.10	Hurricane Kirk Public Advisory Number 22
More »

je.st